Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

医学 内科学 低甲基化剂 阿扎胞苷 中性粒细胞减少症 肿瘤科 髓系白血病 癸他滨 威尼斯人 胃肠病学 发热性中性粒细胞减少症 髓样 白血病 化疗 慢性淋巴细胞白血病 生物 基因 基因表达 DNA甲基化 生物化学
作者
Jayastu Senapati,Warren Fiskus,Naval Daver,Nathaniel R. Wilson,Farhad Ravandi,Guillermo Garcia‐Manero,Tapan M. Kadia,Courtney D. DiNardo,Elias Jabbour,Jan A. Burger,Nicholas J. Short,Yesid Alvarado,Nitin Jain,Lucia Masárová,Ghayas C. Issa,Wei Qiao,Joseph D. Khoury,Sherry Pierce,Darla Miller,Koji Sasaki,Marina Konopleva,Kapil N. Bhalla,Gautam Borthakur,Naveen Pemmaraju
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:29 (21): 4352-4360 被引量:5
标识
DOI:10.1158/1078-0432.ccr-23-1429
摘要

Treatment outcomes in patients with relapsed/refractory (R/R) myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) remains dismal. On the basis of both extensive preclinical data and emerging clinical data, treatment with bromodomain and extra-terminal domain inhibitors (BETi) is a potential approach for patients with high-risk myeloid malignancies.We conducted a phase I trial to study the safety and efficacy of PLX51107 (BETi) and azacitidine combination therapy in patients with R/R AML and high-risk (HR) MDS and studied mechanisms of resistance to the combination therapy.Thirty-seven patients with HR R/R MDS (n = 4) and R/R AML (n = 33) were treated. Sixteen patients (43%) had MECOM gene rearrangement and 7 other patients had TP53 mutation. Median prior number of therapies was three (range 1-9); 97% had received prior hypomethylating agent and 84% prior venetoclax. Overall response rate was 8/37 (22%): complete remission with incomplete platelet recovery (n = 1); morphologic leukemia-free state (n = 2); hematologic improvement (n = 5). The most common nonhematologic toxicities were febrile neutropenia and pneumonia in 12 (32%) patients each; 6 patients (17%) had severe hyperbilirubinemia. RNA-sequencing analysis of mononuclear cells harvested on treatment (day 3) versus pretreatment showed significant changes in mRNA expressions in responders: downregulation of MYC, BCL2, IL7R, and CDK6 and upregulation of HEXIM1, CD93, DCXR, and CDKN1A. Immunoblot analyses confirmed reduction in protein levels of c-Myc, CDK6, BCL2, and BCL-xL, and induction of BRD4 and HEXIM1 protein levels in responders.In a heavily pretreated patient cohort with R/R MDS and AML, PLX51107+ azacitidine was well-tolerated and resulted in modest clinical benefit.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
努力的小饭叽完成签到,获得积分10
刚刚
iNk应助禹代秋采纳,获得10
刚刚
霜月冰发布了新的文献求助10
1秒前
zzz发布了新的文献求助10
1秒前
laohu2发布了新的文献求助10
2秒前
小马甲应助hamzhang0426采纳,获得10
6秒前
李健的小迷弟应助laohu2采纳,获得30
8秒前
9秒前
9秒前
iNk应助gxmu6322采纳,获得10
9秒前
FashionBoy应助lw采纳,获得10
11秒前
11秒前
李鑫完成签到 ,获得积分10
11秒前
搜集达人应助ardejiang采纳,获得10
12秒前
12秒前
12秒前
12秒前
Founder完成签到,获得积分10
13秒前
桐桐应助zzz采纳,获得10
14秒前
lyp完成签到 ,获得积分10
14秒前
霜月冰完成签到,获得积分10
15秒前
Hello应助dddd采纳,获得10
15秒前
在水一方应助fifteen采纳,获得10
16秒前
有情皆苦发布了新的文献求助10
16秒前
笨笨的傲晴完成签到,获得积分10
17秒前
R喵喵发布了新的文献求助20
17秒前
木叶发布了新的文献求助10
21秒前
鹏酱233完成签到,获得积分20
22秒前
俭朴尔岚完成签到,获得积分10
22秒前
和谐晓啸发布了新的文献求助10
24秒前
思源应助sdnihbhew采纳,获得10
24秒前
24秒前
26秒前
苹果饼干发布了新的文献求助10
26秒前
27秒前
ding应助Tangwz采纳,获得10
28秒前
殷勤的觅松完成签到,获得积分10
28秒前
鹏酱233发布了新的文献求助10
28秒前
28秒前
29秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
An Introduction to Geographical and Urban Economics: A Spiky World Book by Charles van Marrewijk, Harry Garretsen, and Steven Brakman 600
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3154423
求助须知:如何正确求助?哪些是违规求助? 2805324
关于积分的说明 7864266
捐赠科研通 2463518
什么是DOI,文献DOI怎么找? 1311381
科研通“疑难数据库(出版商)”最低求助积分说明 629574
版权声明 601821